Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy

Biomaterials

Volumn 33, Issue 7, 2012, Pages 2187-2196

  Zhang, Chuangnian ^a   Wang, Wei ^a   Liu, Tong ^b   Wu, Yukun ^a   Guo, Hua ^a   Wang, Ping ^a   Tian, Qin ^a   Wang, Yongming ^c   Yuan, Zhi ^a  

^a NANKAI UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor; Biodistribution; Glycyrrhetinic acid; Liver targeting; Liver tumors in situ

Indexed keywords

ANTI-TUMOR ACTIVITIES; ANTI-TUMORS; BIODISTRIBUTIONS; DOXORUBICIN; EXPERIMENTAL GROUPS; HEART CELLS; HISTOLOGICAL EXAMINATION; IN-SITU; INTRAVENOUS ADMINISTRATION; KUNMING MOUSE; LIVER CANCERS; LIVER CELLS; LIVER TARGETING; LIVER TUMORS; LIVER TUMORS IN SITU; SAMPLING TIME; SIDE EFFECT; TUMOR NECROSIS;

CELLS; CHEMOTHERAPY; MAMMALS; NANOPARTICLES;

TUMORS;

ALGINIC ACID; DOXORUBICIN; GLYCYRRHETINIC ACID; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG RELEASE; DRUG TARGETING; HEART MUSCLE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LIVER CANCER; LIVER CELL; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR NECROSIS;

ALGINATES; ANIMALS; CELL LINE, TUMOR; DOXORUBICIN; DRUG CARRIERS; GLUCURONIC ACID; GLYCYRRHETINIC ACID; HEXURONIC ACIDS; HUMANS; LIVER NEOPLASMS; MATERIALS TESTING; MICE; MOLECULAR STRUCTURE; NANOPARTICLES; TISSUE DISTRIBUTION;

MUS;

EID: 84855739069     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.11.045     Document Type: Article

References (40)

1. El-Serag H.B., Rudolph L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
2. Working P.K., Newman M.S., Sullivan T., Yarrington J. Reduction of the cardiotoxicity of doxorubicin in rabbits and dogs by encapsulation in long-circulating, pegylated liposomes. JPharmacol Exp Ther 1999, 289:1128-1133.
3. Dufes C., Muller J.M., Couet W., Olivier J.C., Uchegbu I.F., Schatzlein A.G. Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles. Pharm Res-Dordr 2004, 21:101-107.
4. Dong L., Xia S.H., Wu K., Huang Z., Chen H.A., Chen J.N., et al. ApH/enzyme-responsive tumor-specific delivery system for doxorubicin. Biomaterials 2010, 31:6309-6316.
5. Brannon-Peppas L., Blanchette J.O. Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliver Rev 2004, 56:1649-1659.
6. Lammers T., Hennink W.E., Storm G. Tumour-targeted nanomedicines: principles and practice. Brit J Cancer 2008, 99:392-397.
7. Wang M.D., Shin D.M., Simons J.W., Nie S.M. Nanotechnology for targeted cancer therapy. Expert Rev Anticanc 2007, 7:833-837.
8. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2:750-763.
9. Xiong X.B., Huang Y., Lu W.L., Zhang X., Zhang H., Nagai T., et al. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: invitro and invivo. JPharm Sci-Us 2005, 94:1782-1793.
10. Kim D., Gao Z.G., Lee E.S., Bae Y.H. Invivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Mol Pharmaceut 2009, 6:1353-1362.
11. Liang H.F., Chen C.T., Chen S.C., Kulkarni A.R., Chiu Y.L., Chen M.C., et al. Paclitaxel-loaded poly(gamma-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials 2006, 27:2051-2059.
12. Negishi M., Irie A., Nagata N., Ichikawa A. Specific binding of glycyrrhetinic acid to the rat liver membrane. Biochim Biophys Acta 1991, 1066:77-82.
13. Mao S.J., Bi Y.Q., Jin H., Wei D.P., He R., Hou S.X. Preparation, characterization and uptake by primary cultured rat hepatocytes of liposomes surface-modified with glycyrrhetinic acid. Pharmazie 2007, 62:614-619.
14. Huang W., Wang W., Wang P., Tian Q., Zhang C., Wang C., et al. Glycyrrhetinic acid-modified poly(ethylene glycol)-b-poly(gamma-benzyl l-glutamate) micelles for liver targeting therapy. Acta Biomater 2010, 6:3927-3935.
15. Tsuji H., Osaka S., Kiwada H. Targeting of liposomes surface-modified with glycyrrhizin to the liver. I. Preparation and biological disposition. Chem Pharm Bull 1991, 39:1004-1008.
16. Tian Q., Zhang C.N., Wang X.H., Wang W., Huang W., Cha R.T., et al. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials 2010, 31:4748-4756.
17. Janes K.A., Calvo P., Alonso M.J. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliver Rev 2001, 47:83-97.
18. Liu Z.H., Jiao Y.P., Wang Y.F., Zhou C.R., Zhang Z.Y. Polysaccharides-based nanoparticles as drug delivery systems. Adv Drug Deliver Rev 2008, 60:1650-1662.
19. Tonnesen H.H., Karlsen J. Alginate in drug delivery systems. Drug DevInd Pharm 2002, 28:621-630.
20. Augst A.D., Kong H.J., Mooney D.J. Alginate hydrogels as biomaterials. Macromol Biosci 2006, 6:623-633.
21. Yang L.Q., Zhang B.F., Wen L.Q., Liang Q.Y., Zhang L.M. Amphiphilic cholesteryl grafted sodium alginate derivative: synthesis and self-assembly in aqueous solution. Carbohyd Polym 2007, 68:218-225.
22. Zhang C.N., Wang W., Wang C.H., Tian Q., Huang W., Yuan Z., et al. Cytotoxicity of liver targeted drug-loaded alginate nanoparticles. Sci China Ser B 2009, 52:1382-1387.
23. Ma P.A., Liu S., Huang Y.B., Chen X.S., Zhang L.P., Jing X.B. Lactose mediated liver-targeting effect observed by exvivo imaging technology. Biomaterials 2010, 31:2646-2654.
24. Wang J.X., Sun X., Zhang Z.R. Enhanced brain targeting by synthesis of 3 ',5 '-dioctanoyl-5-fluoro-2 '-deoxyuridine and incorporation into solid lipid nanoparticles. Eur J Pharm Biopharm 2002, 54:285-290.
25. Zhang Z.M., Yang X.Y., Deng S.H., Xu W., Gao H.Q. Anti-tumor effects of polybutylcyanoacrylate nanoparticles of diallyl trisulfide on orthotopic transplantation tumor model of hepatocellular carcinoma in BALB/c nude mice. Chin Med J-Peking 2007, 120:1336-1342.
26. Ma H.L., Qi X.T., Maitani Y., Nagai T. Preparation and characterization of superparamagnetic iron oxide nanoparticles stabilized by alginate. Int J Pharm 2007, 333:177-186.
27. Yu C.Y., Jia L.H., Yin B.C., Zhang X.Z., Cheng S.X., Zhuo R.X. Fabrication of nanospheres and vesicles as drug carriers by self-assembly of alginate. JPhys Chem C 2008, 112:16774-16778.
28. Lu B., Wu C.R., Yang W.Y., Wei Y. The binding of bifunctional reagents to silanized silicon surfaces studied by angle-dependent X-ray photoelectron spectroscopy. Appl Surf Sci 1993, 72:125-132.
29. Park E.K., Lee S.B., Lee Y.M. Preparation and characterization of methoxy poly(ethylene glycol)/poly(epsilon-caprolactone) amphiphilic block copolymeric nanospheres for tumor-specific folate-mediated targeting of anticancer drugs. Biomaterials 2005, 26:1053-1061.
30. Wike-Hooley J.L., Haveman J., Reinhold H.S. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 1984, 2:343-366.
31. Suo A.L., Qian J.M., Yu Yao, Zhang W.G. Galactosylated poly(ethylene glycol)-b-poly (l-lactide-co-β-malic acid) block copolymer micelles for targeted drug delivery: preparation and invitro characterization. Int J Nanomed 2010, 5:1029-1038.
32. Yu J.J., Lee H.A., Kim J.H., Kong W.H., Kim Y., Cui Z.Y., et al. Bio-distribution and anti-tumor efficacy of PEG/PLA nano particles loaded doxorubicin. JDrug Target 2007, 15:279-284.
33. Dromi S., Frenkel V., Luk A., Traughber B., Angstadt M., Bur M., et al. Pulsed-high intensity focused ultrasound and low temperature sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res 2007, 13:2722-2727.
34. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Advan Enzyme Regul 2001, 41:189-207.
35. Maeng J.H., Lee D.H., Jung K.H., Bae Y.H., Park I.S., Jeong S., et al. Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials 2010, 31:4995-5006.
36. Chan J.M., Zhang L.F., Yuet K.P., Liao G., Rhee J.W., Langer R., et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 2009, 30:1627-1634.
37. Li L.L., Tang F.Q., Liu H.Y., Liu T.L., Hao N.J., Chen D., et al. Invivo delivery of silica nanorattle encapsulated docetaxel for liver cancer therapy with low toxicity and high efficacy. ACS Nano 2010, 4:6874-6882.
38. Guillemard V., Saragovi H.U. Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors invivo with high efficacy and target-dependent selectivity. Oncogene 2004, 23:3613-3621.
39. Gao J.M., Qian F., Szymanski-Exner A., Stowe N., Haaga J. Invivo drug distribution dynamics in thermoablated and normal rabbit livers from biodegradable polymers. JBiomed Mater Res 2002, 62:308-314.
40. Wang X., Li J., Wang Y., Koenig L., Gjyrezi A., Giannakakou P., et al. Afolate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model. ACS Nano 2011, 5:6184-6194.